Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TCM Biotech InternationalTPE:4169 -2.48%52 EV-to-FCF is 372.59 as of Aug. 10, 2026, which is 7% above its 10-year median of 347.85. GuruFocus rates TPE:4169 with a GF Score™ of 52/100 and a GF Value™ of NT$42.31 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 334 Biotechnology companies, TCM Biotech International ranks worse than 96.11% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TCM Biotech International's Enterprise Value is NT$9,861.6 Mil.
TCM Biotech International's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was NT$26.5 Mil. Therefore, TCM Biotech International's EV-to-FCF for today is 372.59.
The historical rank and industry rank for TCM Biotech International's EV-to-FCF or its related term are showing as below:
TPE:4169'
s EV-to-FCF Range Over the Past 10 Years
Min: -1781.23 Med: 347.85 Max: 1552.19
Current: 372.59
During the past 13 years, the highest EV-to-FCF of TCM Biotech International was 1552.19. The lowest was -1781.23. And the median was 347.85.
TPE:4169's EV-to-FCF is ranked worse than 96.11% of 334
companies
in the Biotechnology industry
Industry Median: 17.55
vs TPE:4169: 372.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TCM Biotech International (TPE:4169) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TCM Biotech International's PE Ratio (TTM) for today is calculated as:
TCM Biotech International's share price for today is NT$157.00.
TCM Biotech International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TCM Biotech International EV-to-FCF Related Terms
TCM Biotech International EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4169 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, TCM Biotech International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's EV-to-FCF falls into.
TCM Biotech International's current Enterprise Value is NT$9,861.6 Mil.
TCM Biotech International's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$26.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCM Biotech International (TPE:4169) has a EV-to-FCF of 372.59 as of Aug. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TCM Biotech International and its competitors. This is near median its historical median of 347.85. According to the industry distribution chart, TCM Biotech International ranks #321 out of 334 companies in the Biotechnology industry, placing it in the top 96.1%.
Is TCM Biotech International's EV-to-FCF too high?
TCM Biotech International's current EV-to-FCF of 372.59 is near median its 10-year median of 347.85. The Biotechnology industry median EV-to-FCF is 17.55. TCM Biotech International's value of 372.59 is 2023% above this industry median. Based on the distribution chart, TCM Biotech International ranks #321 out of 334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TCM Biotech International ranks #321 out of 334 companies for EV-to-FCF. This places TCM Biotech International in the lower half of its industry. The industry median EV-to-FCF is 17.55. TCM Biotech International's value of 372.59 is 2023% above this benchmark. While the company's 10-year median is 347.85 vs. the industry median of 17.55, TCM Biotech International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.55, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TCM Biotech International's current EV-to-FCF of 372.59 is 2023% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TCM Biotech International and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TCM Biotech International's current EV-to-FCF is 372.59, which is near median its own 10-year median of 347.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$157.00 — trading 271.1% above its estimated fair value. The current EV-to-FCF is 372.59, which is near median its 10-year median of 347.85 and 2023% above the Biotechnology industry median of 17.55. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current EV-to-FCF is 372.59 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TCM Biotech International (TPE:4169) Overvalued in 2026?
Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued.
The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31.
GuruFocus considers TCM Biotech International to be Significantly Overvalued.
Key valuation signals for TPE:4169:
EV-to-FCF: 372.59 (near median its 10-year median of 347.85)
GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
Industry Position: 2023% above the Biotechnology median (#321 of 334)
No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score
Get the complete analysis for TPE:4169
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4169 has been successfully added to your 
